Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

British Journal of Psychiatry

Volumn 179, Issue OCT., 2001, Pages 290-299

  Adams, C E ^a   Fenton, M K P ^a   Quraishi, S ^a   David, A S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMPERIDOL DECANOATE; FLUPENTIXOL; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; FLUSPIRILENE; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; PERPHENAZINE; PIPOTIAZINE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; META ANALYSIS; MOTOR DYSFUNCTION; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; DATABASES, BIBLIOGRAPHIC; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RISK; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0034776721     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.179.4.290     Document Type: Review

References (42)

1. Depot fluphenazine for schizophrenia
2. The comprehensive psychopathological scale
3. Long-term depot antipsychotics. A risk-benefit assessment
4. Improving the quality of reporting of randomised controlled trials. The CONSORT statement
5. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use
6. Médication antiparkinsonienne et bilan extrapyramidal. Étude du trihexyphenidyl
7. Bias in treatment assignment in controlled clinical trials
8. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses
9. The natural course of schizophrenia and effective maintenance drug treatment
10. Depot antipsychotic drugs. Place in therapy
11. Determinants of medication compliance in schizophrenia: Empirical and clinical findings
12. Adults with a psychotic disorder living in the community
13. Depot neuroleptics in relapse prevention: Advantages and disadvantages
14. Publication bias and the integrity of psychiatry research
15. Depot neuroleptic therapy: An underutilized treatment option
16. A rating scale for depression
17. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: Double-blind placebo controlled trial
18. NOSIE-30: A treatment sensitive ward behavior scale
19. Pragmatic randomised controlled trials in psychiatry
20. Methodology and reports of systematic reviews and meta-analyses: A comparison of Cochrane reviews with articles published in paper-based journals
21. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia
22. Guidelines for depot antipsychotic treatment in schizophrenia
23. Insight and compliance
24. Standardised psychiatric assessment scale for chronic psychiatric patients
25. The UKU side effects rating scale
26. Development of a schizophrenia scale sensitive to change
27. The brief psychiatric rating scale
28. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders
29. Depot fluspirilene for schizophrenia
30. Depot haloperidol decanoate for schizophrenia
31. Depot perphenazine decanoate and enanthate for schizophrenia
32. Depot pipothiazine palmitate and undecylenate for schizophrenia
33. Depot bromperidol decanoate for schizophrenia
34. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
35. A brief history of depot neuroleptics
36. A rating scale for extrapyramidal side effects
37. Content and quality of 2000 controlled trials in schizophrenia over 50 years
38. Systematic review of patient and nurse attitudes to depot antipsychotic medication
39. Cost of relapse in schizophrenia
40. A simple and reliable subclassification of chronic schizophrenia